BREAKING ADVANCES

5681 Highlights from Recent Cancer Literature

REVIEW

5683 DEAR1, a Novel Tumor Suppressor That Regulates Cell Polarity and Epithelial Plasticity
Nanyue Chen, Seetharaman Balasenthil, Jacquelyn Reuther, and Ann McNeill Killary

INTEGRATED SYSTEMS AND TECHNOLOGIES

5690 Novel Drug Candidates for the Treatment of Metastatic Colorectal Cancer through Global Inverse Gene-Expression Profiling
Vera van Noort, Sebastian Schölch, Murat Iskar, Georg Zeller, Kristina Ostertag, Christine Schweitzer, Kristin Werner, Jürgen Weitz, Moritz Koch, and Peer Bork

5700 Development of Novel ADCs: Conjugation of Tubulysin Analogues to Trastuzumab Monitored by Dual Radiolabeling
Ruth Cohen, Danielle J. Vugts, Gerard W.M. Visser, Marijke Stigter-van Walsum, Marije Bolijn, Marco Spiga, Paolo Lazzari, Sreejith Shankar, Monica Sani, Matteo Zanda, and Guus A.M.S. van Dongen

MICROENVIRONMENT AND IMMUNOLOGY

5711 Adiponectin Receptor Signaling on Dendritic Cells Blunts Antitumor Immunity
Peng H. Tan, Helen E.J. Tyrrell, Liqian Gao, Danmei Xu, Jianchao Quan, Dipender Gill, Lena Rai, Yunchuan Ding, Gareth Plant, Yuan Chen, John Z. Xue, Ashok I. Handa, Michael J. Greenall, Kenneth Walsh, and Shao-An Xue

5723 HMGB1 Enhances Immune Suppression by Facilitating the Differentiation and Suppressive Activity of Myeloid-Derived Suppressor Cells
Katherine H. Parker, Pratima Sinha, Lucas A. Horn, Virginia K. Clements, Huan Yang, Jianhua Li, Kevin J. Tracey, and Suzanne Ostrander-Rosenberg

5734 Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy
Jing Huang, Lin Xiao, Xiaoting Gong, Wenwei Shao, Yanhui Yin, Qinyuan Liao, Yang Meng, Yingmei Zhang, Dalong Ma, and Xiaoyan Qiu

5746 Metastatic Consequences of Immune Escape from NK Cell Cytotoxicity by Human Breast Cancer Stem Cells
Bin Wang, Qiang Wang, Zhe Wang, Jun Jiang, Shi-Cang Yu, Yi-Fang Ping, Jing Yang, Sen-Lin Xu, Xian-Zong Ye, Chuan Xu, Lang Yang, Cheng Qian, Ji Ming Wang, You-Hong Cui, Xia Zhang, and Xiu-Wu Bian

5758 Cellular Disposal of miR23b by RAB27-Dependent Exosome Release Is Linked to Acquisition of Metastatic Properties

MOLECULAR AND CELLULAR PATHOBIOLGY

5723HMGB1 Enhances Immune Suppression by Facilitating the Differentiation and Suppressive Activity of Myeloid-Derived Suppressor Cells
Katherine H. Parker, Pratima Sinha, Lucas A. Horn, Virginia K. Clements, Huan Yang, Jianhua Li, Kevin J. Tracey, and Suzanne Ostrander-Rosenberg

5734Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy
Jing Huang, Lin Xiao, Xiaoting Gong, Wenwei Shao, Yanhui Yin, Qinyuan Liao, Yang Meng, Yingmei Zhang, Dalong Ma, and Xiaoyan Qiu

5746Metastatic Consequences of Immune Escape from NK Cell Cytotoxicity by Human Breast Cancer Stem Cells
Bin Wang, Qiang Wang, Zhe Wang, Jun Jiang, Shi-Cang Yu, Yi-Fang Ping, Jing Yang, Sen-Lin Xu, Xian-Zong Ye, Chuan Xu, Lang Yang, Cheng Qian, Ji Ming Wang, You-Hong Cui, Xia Zhang, and Xiu-Wu Bian

5758Cellular Disposal of miR23b by RAB27-Dependent Exosome Release Is Linked to Acquisition of Metastatic Properties

Précis: This interesting study suggests that exosome secretion serves as a disposal mechanism for tumor suppressor microRNA during tumor progression, thereby enabling the acquisition of metastatic capabilities.
The 19q12 Bladder Cancer GWAS Signal: Genetic Drivers of aggressive bladder cancer

5808

The 19q12 Bladder Cancer GWAS Signal: Association with Cyclin E Function and Aggressive Disease

Yi-Fing Fu, Indu Kohar, Lee E. Moore, Petra Lenz, Jonine D. Figueroa, Wei Tang, Patricia Porter-Gill, Wanyuan Chen, Xingjie He, and Chengchao Shou

**Précis:** This study reveals that the survival of endometrial cancer cells relies critically on GLUT6-mediated glucose transport, along with glycolytic and lipogenic metabolic pathways, with implications for therapeutic strategies in this setting.

5832

Metabolic Vulnerabilities in Endometrial Cancer


**Précis:** This study reports key progress in identifying a marker of aggressive behavior in bladder cancer, a disease in which there has been a paucity of knowledge about key genetic drivers.

5819

Copper Signaling Axis as a Target for Prostate Cancer Therapeutics


**Précis:** Clinical trials in oncology of an approved dithiol compound have failed to produce efficacy, but the findings of this study suggest that this compound should be reexplored with the addition of copper to the regimen, particularly with regard to treatment of prostate cancers resistant to androgen ablation.
**In Vivo Localization of $^{90}$Y and $^{177}$Lu Radioimmunoconjugates Using Cerenkov Luminescence Imaging in a Disseminated Murine Leukemia Model**

Ethan R. Balkin, Aimee Kenoyer, Johnnie J. Orozco, Alexandra Hernandez, Maziyar Shadman, Darrell R. Fisher, Damian J. Green, Mark D. Hyland, Oliver W. Press, D. Scott Wilbur, and John M. Pagel

**Précis:** Results demonstrate the feasibility of using a novel noninvasive imaging technique called Cerenkov Light Imaging (CLI) to optimize the use of radioimmunoconjugates used to treat aggressive leukemias.

---

**SAR405838: An Optimized Inhibitor of MDM2–p53 Interaction That Induces Complete and Durable Tumor Regression**

Shaomeng Wang, Wei Sun, Yujun Zhao, Donna McEachern, Isabelle Meaux, Cédric Barrière, Jeanne A. Stuckey, Jennifer L. Meagher, Longchuan Bai, Liu Liu, Cassandra Gianna Hoffman-Luca, Jianfeng Lu, Sanjeev Shangary, Shanghai Yu, Denzil Bernard, Angelo Aguilar, Odette Dos-Santos, Laurent Besret, Stéphane Gueff, Pascal Pannier, Dimitri Gorge-Bernat, and Laurent Debussche

**Précis:** Despite the risk of applying a selection for p53 mutations that escape MDM2 control, blocking MDM2-p53 protein–protein interaction has long been considered by many to offer an attractive cancer therapeutic strategy, a position strongly supported by the findings of this preclinical study.

---

**Dsh Homolog DVL3 Mediates Resistance to IGFIR Inhibition by Regulating IGF-RAS Signaling**

Shan Gao, Ilirjana Bajrami, Clare Verrill, Asha Kigozi, Djamila Ouaret, Tamara Aleksic, Ruth Asher, Cheng Han, Paul Allen, Deborah Bailey, Stephan Feller, Takeshi Kashima, Nicholas Athanasou, Jean-Yves Blay, Sandra Schmitz, Jean-Pascal Machiels, Nav Upile, Terry M. Jones, George Thalmann, Shazad Q. Ashraf, Jennifer L. Wilding, Walter F. Bodmer, Mark R. Middleton, Alan Ashworth, Christopher J. Lord, and Valentine M. Macaulay

**Précis:** This mechanistic study is important because it addresses the lack of predictive biomarkers for stratifying and recruiting cancer patients who might benefit from IGF-1 inhibitors, a key gap in their clinical development as cancer drugs.

---

**AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs**

Catherine Wilson, Xiaofen Ye, Thinh Pham, Eva Lin, Sara Chan, Erin McNamara, Richard M. Neve, Lisa Belmont, Hartmut Koeppen, Robert L. Yauch, Avi Ashkenazi, and Jeff Settleman

**Précis:** These findings challenge a purported role for AXL in drug resistance while offering a novel rationale to combine AXL-targeting drugs with antimitotic agents to eradicate invasive cancers.

---

**TUMOR AND STEM CELL BIOLOGY**

**β-Catenin Contributes to Lung Tumor Development Induced by EGFR Mutations**


**Précis:** Drug resistance to EGF receptor antagonists in lung cancer may be mediated in part by activation of the β-catenin pathway, reinforcing its importance as an oncogenic driver in this setting.

---

**MYC Activates Stem-like Cell Potential in Hepatocarcinoma by a p53-Dependent Mechanism**

Hirofumi Akita, Jens U. Marquardt, Marian E. Durkin, Mitsuteru Kitade, Daekwan Seo, Elizabeth A. Conner, Jesper B. Andersen, Valentina M. Factor, and Snorri S. Thorgeransson

**Précis:** Cancer stem-like cell populations in liver cancer appear to be expanded under conditions in which MYC is activated and p53 is downregulated, with potential implications for understanding etiology, progression, and treatment in this disease.

---

**Zfx Facilitates Tumorigenesis Caused by Activation of the Hedgehog Pathway**

Colin J. Palmer, Jose M. Galan-Caridad, Stuart P. Weisberg, Liang Lei, Jose M. Esquillín, Gist F. Croft, Brandon Wainwright, Peter Canoll, David M. Owens, and Boris Reizis

**Précis:** This preclinical genetic study identifies new candidate targets for the control of tumors driven by the Hedgehog pathway, the aberrant activation of which has been implicated widely in many types of human solid tumors.
SIRT6 Promotes COX-2 Expression and Acts as an Oncogene in Skin Cancer
Mei Ming, Weinong Han, Baozhong Zhao, Nagalingam R. Sundaesan, Chu-Xia Deng, Mahesh P. Gupta, and Yu-Ying He

Précis: This study challenges an existing view of the Sir2-related protein SIRT6 as a tumor suppressor, finding instead in a genetically deficient mouse that it functions as an oncogene in the skin epidermis.

ABOUT THE COVER

The AXL receptor tyrosine kinase has been implicated as a cellular signaling protein that is specifically upregulated in the context of the epithelial-to-mesenchymal transformation seen in some epithelial cancers and the emergence of acquired drug resistance. Among the tumor types in which a mesenchymal, largely drug-refractory phenotype appears to be prevalent is triple-negative breast cancer (TNBC). This immunohistological image illustrates the expression of AXL in a TNBC tumor specimen, revealing punctate cytoplasmic staining of AXL in tumor cells as well as focal vascular staining. For details, see article by Wilson and colleagues on page 5878.